Boston Scientific's stent opens blood vessels and European markets

Boston Scientific's ($BSX) launch of its below-the-knee, everolimus-eluting stent system to treat critical limb ischemia, known as Promus Element Plus in Europe, will open up a major potential market for the company--there are around 500 to 1,000 new cases of critical limb ischemia per million people every year in Europe. The disease, which obstructs the arteries and cuts blood flow to the feet and legs, can lead to pain, non-healing wounds, gangrene and even amputation. Stents reopen the blood vessels and the addition of slow-release everolimus helps prevent them from blocking again. Press release

Suggested Articles

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.

Swiss scientists are using ultrasound to trap and deliver drugs in the brain, a non-invasive delivery method that could help target tumors, too.